Lamivudine resistance of HIV type 1 does not delay development of resistance to nonnucleoside HIV type 1-specific reverse transcriptase inhibitors as compared with wild-type HIV type 1

被引：22

作者：

Jonckheere, H ^{[1
]}

Witvrouw, M ^{[1
]}

De Clercq, E ^{[1
]}

Anné, J ^{[1
]}

机构：

[1] Rega Inst Med Res, B-3000 Louvain, Belgium

来源：

AIDS RESEARCH AND HUMAN RETROVIRUSES | 1998年 / 14卷 / 03期

关键词：

D O I：

10.1089/aid.1998.14.249

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We compared the development of resistance toward BI-RG-587 (nevirapine) and alpha-APA R89439 (loviride) starting from the wild-type HIV-1 strain IIIB and the 3TC-resistant HIV-1 strain containing the M184V mutation. The reverse transcriptase of the M184V mutant has been reported to have a higher fidelity. Our experiments showed that there was no significant delay in virus breakthrough of the M184V mutant as compared with the wild-type virus. We therefore conclude that the reported higher fidelity of the M184V mutant does not lead to a delay in the development of resistance to the nonnucleoside reverse transcriptase inhibitors nevirapine and loviride.

引用

收藏

页码：249 / 253

页数：5

相关论文

共 16 条

[1] Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme [J].

Back, NKT ;

Nijhuis, M ;

Keulen, W ;

Boucher, CAB ;

Essink, BBO ;

vanKuilenburg, ABP ;

vanGennip, AH ;

Berkhout, B .

EMBO JOURNAL, 1996, 15 (15) :4040-4049

[2]

Balzarini J, 1996, MOL PHARMACOL, V49, P882

[3] Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors [J].

Balzarini, J ;

Pelemans, H ;

Karlsson, A ;

DeClercq, E ;

Kleim, JP .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (23) :13152-13157

[4] RAPID TURNOVER OF PLASMA VIRIONS AND CD4 LYMPHOCYTES IN HIV-1 INFECTION [J].

HO, DD ;

NEUMANN, AU ;

PERELSON, AS ;

CHEN, W ;

LEONARD, JM ;

MARKOWITZ, M .

NATURE, 1995, 373 (6510) :123-126

[5] In vitro selection for different mutational patterns in the HIV-1 reverse transcriptase using high and low selective pressure of the nonnucleoside reverse transcriptase inhibitor HBY 097 [J].

Kleim, JP ;

Winkler, I ;

Rosner, M ;

Kirsch, R ;

RubsamenWaigmann, H ;

Paessens, A ;

Riess, G .

VIROLOGY, 1997, 231 (01) :112-118

[6]

Miyoshi I., 1982, GANN MONOGR, V28, P219

[7]

MOEREMANS M, 1995, 4 INT WORKSH HIV DRU, P34

[8] POTENT AND HIGHLY SELECTIVE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1) INHIBITION BY A SERIES OF ALPHA-ANILINOPHENYLACETAMIDE DERIVATIVES TARGETED AT HIV-1 REVERSE-TRANSCRIPTASE [J].

PAUWELS, R ;

ANDRIES, K ;

DEBYSER, Z ;

VAN DAELE, P ;

SCHOLS, D ;

STOFFELS, P ;

DEVREESE, K ;

WOESTENBORGHS, R ;

VANDAMME, AM ;

JANSSEN, CGM ;

ANNE, J ;

CAUWENBERGH, G ;

DESMYTER, J ;

HEYKANTS, J ;

JANSSEN, MAC ;

DE CLERCQ, E ;

JANSSEN, PAJ .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (05) :1711-1715

[9] RAPID AND AUTOMATED TETRAZOLIUM-BASED COLORIMETRIC ASSAY FOR THE DETECTION OF ANTI-HIV COMPOUNDS [J].

PAUWELS, R ;

BALZARINI, J ;

BABA, M ;

SNOECK, R ;

SCHOLS, D ;

HERDEWIJN, P ;

DESMYTER, J ;

DECLERCQ, E .

JOURNAL OF VIROLOGICAL METHODS, 1988, 20 (04) :309-321

[10] Reverse transcriptase fidelity and HIV-1 variation [J].

Preston, BD .

SCIENCE, 1997, 275 (5297) :228-229